ProfileGDS5678 / 1430458_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 47% 47% 47% 47% 55% 57% 50% 47% 49% 48% 47% 52% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3424853
GSM967853U87-EV human glioblastoma xenograft - Control 23.1179147
GSM967854U87-EV human glioblastoma xenograft - Control 33.0957447
GSM967855U87-EV human glioblastoma xenograft - Control 43.0388747
GSM967856U87-EV human glioblastoma xenograft - Control 53.0581347
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4644255
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5372957
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1795250
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0824447
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1602149
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1261848
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0614847
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2893252
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6013560